Compared with trastuzumab, our HER2-CD3-Fc bsAb has a CD3 scFv that recruits and activates effector T cells to attack HER2-positive tumor cells and, thus, potentially offers better and more potent antitumor effects [30,32,73]. The gene discussed is ERBB2; the disease is neoplasm.